Charles River Accelerates Cell Banking with Rapid Methods and NGS
Event summary
- Charles River introduced rapid cell banking programs to reduce release timelines for biopharmaceutical and advanced therapy developers.
- The company combines rapid cell bank and release packages with Next-Generation Sequencing (NGS) for comprehensive characterization.
- Charles River's Alternative Methods Advancement Project (AMAP) aims to reduce reliance on animal testing.
- The acquisition of Pathoquest strengthens Charles River's NGS capabilities for in vitro characterization and quality control testing.
The big picture
Charles River's new rapid cell banking programs address the growing need for faster development timelines in the biopharmaceutical and advanced therapy sectors. The integration of NGS technologies and the focus on reducing animal testing align with broader industry trends toward efficiency and regulatory compliance. The acquisition of Pathoquest further solidifies Charles River's position as a leader in innovative testing solutions.
What we're watching
- Adoption Pace
- How quickly biopharmaceutical developers will integrate Charles River's rapid cell banking programs into their workflows.
- Regulatory Alignment
- Whether the NGS-based testing solutions will consistently meet FDA, EMA, and ICH regulatory expectations.
- Competitive Edge
- The extent to which Charles River's AMAP initiative differentiates it from competitors in reducing animal testing reliance.
Related topics